Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The Structural Genomics Consortium Oxford is leading a new open-access platform to generate novel high-quality reproducible and renewable antibodies for both established and novel ALS genes and variants. Working in partnership with the ALS Association (US), the Motor Neurone Disease Association (UK) and the ALS Society of Canada, the SGC labs at the University of Oxford, Karolinska Institutet and Montreal Neurological Institute will jointly generate up to 75 novel renewable, fully validated high-quality antibodies for up to 45 novel ALS-associated genes (and variants).